Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRAL II: Osimertinib plus bevacizumab in untreated EGFR-mutated NSCLC with malignant pleural/pericardial effusion
jRCTs071180004Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib and bevacizumab in non-small cell lung cancer (NSCLC), malignant pleural effusion (MPE) and malignant pericardial effusion (MPE), sponsored by AstraZeneca. Primary endpoint: 1-year progression-free survival rate. Started Jan 2019; status: completed.
02
Drugs
osimertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)malignant pleural effusion (MPE)malignant pericardial effusion (MPE)
Beyond the preview
Go deeper on jRCTs071180004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180004.